SAB Biotherapeutics, Inc. SABS
3.29
(0.06)
(1.79%)
as of 25 Sep
- Market cap
- $304.8M
- P/E
- 0.0×
Follow SABS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(21.16%) | 4.80% | (7.57%) | (19.21%) | |
| (18.01%) | 3.93% | (6.57%) | (16.24%) | ||
ROIC |
(47.07%) | (52.73%) | (29.58%) | (38.97%) | |
Return on Tangible Assets |
(18.48%) | 4.11% | (8.06%) | (19.72%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.53) | (2.37) | (0.99) | (0.72) | |
Free Cash Flow |
(37.59) | (45.71) | (53.16) | (57.44) | |
Capital Expenditures |
(0.05) | (0.93) | (1.91) | (3.50) | |
| Other line items | |||||
Cash ROIC |
(13.45%) | (17.82%) | (15.17%) | (16.83%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.76 | (10.51) | 5.45 | 2.48 | |
Depreciation/Fixed assets |
0.23 | 0.22 | 0.22 | 0.21 | |
Capex/Depreciation |
(0.02) | (0.31) | (0.64) | (1.16) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.52) | (2.32) | (0.96) | (0.68) | |
Capex per Share |
(0.01) | (0.05) | (0.04) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates